Biotech / Clinical Data
MacroGenics reports 27% response rate for MGC026 in pretreated head and neck cancer
Six of 22 response-evaluable patients responded, four of them confirmed, and no patient in the 27-person cohort stopped treatment for a treatment-related event. The filing carries no revenue, cash or per-share figures.